JP2016537380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537380A5 JP2016537380A5 JP2016532586A JP2016532586A JP2016537380A5 JP 2016537380 A5 JP2016537380 A5 JP 2016537380A5 JP 2016532586 A JP2016532586 A JP 2016532586A JP 2016532586 A JP2016532586 A JP 2016532586A JP 2016537380 A5 JP2016537380 A5 JP 2016537380A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- administered
- inh
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907550P | 2013-11-22 | 2013-11-22 | |
| US61/907,550 | 2013-11-22 | ||
| US201462029086P | 2014-07-25 | 2014-07-25 | |
| US62/029,086 | 2014-07-25 | ||
| PCT/US2014/066784 WO2015077543A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018194167A Division JP6620206B2 (ja) | 2013-11-22 | 2018-10-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537380A JP2016537380A (ja) | 2016-12-01 |
| JP2016537380A5 true JP2016537380A5 (https=) | 2017-12-07 |
| JP6431912B2 JP6431912B2 (ja) | 2018-11-28 |
Family
ID=52016153
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532586A Active JP6431912B2 (ja) | 2013-11-22 | 2014-11-21 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2018194167A Active JP6620206B2 (ja) | 2013-11-22 | 2018-10-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2018214342A Withdrawn JP2019023233A (ja) | 2013-11-22 | 2018-11-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2021012833A Withdrawn JP2021063141A (ja) | 2013-11-22 | 2021-01-29 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2022163044A Pending JP2022179637A (ja) | 2013-11-22 | 2022-10-11 | 臓器移植患者における抗体媒介性拒絶反応のｃ１－エステラーゼ阻害剤を使用した治療方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018194167A Active JP6620206B2 (ja) | 2013-11-22 | 2018-10-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2018214342A Withdrawn JP2019023233A (ja) | 2013-11-22 | 2018-11-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2021012833A Withdrawn JP2021063141A (ja) | 2013-11-22 | 2021-01-29 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2022163044A Pending JP2022179637A (ja) | 2013-11-22 | 2022-10-11 | 臓器移植患者における抗体媒介性拒絶反応のｃ１－エステラーゼ阻害剤を使用した治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9895428B2 (https=) |
| EP (3) | EP4162947A1 (https=) |
| JP (5) | JP6431912B2 (https=) |
| KR (2) | KR102312817B1 (https=) |
| CN (2) | CN111388655A (https=) |
| AU (2) | AU2014352846B2 (https=) |
| BR (1) | BR112016011499A2 (https=) |
| CA (1) | CA2930964A1 (https=) |
| CY (1) | CY1121298T1 (https=) |
| DK (1) | DK3071219T3 (https=) |
| ES (1) | ES2708655T3 (https=) |
| HR (1) | HRP20190184T1 (https=) |
| HU (1) | HUE041809T2 (https=) |
| LT (1) | LT3071219T (https=) |
| ME (1) | ME03318B (https=) |
| MX (2) | MX378834B (https=) |
| NZ (2) | NZ719724A (https=) |
| PL (1) | PL3071219T3 (https=) |
| PT (1) | PT3071219T (https=) |
| RS (1) | RS58343B1 (https=) |
| SG (1) | SG10201804326SA (https=) |
| SI (1) | SI3071219T1 (https=) |
| SM (1) | SMT201900042T1 (https=) |
| WO (1) | WO2015077543A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ719724A (en) * | 2013-11-22 | 2022-08-26 | Takeda Pharmaceuticals Co | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| CA3075686A1 (en) * | 2017-09-15 | 2019-03-21 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
| WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| US20220073605A1 (en) * | 2018-12-20 | 2022-03-10 | Cedars-Sinai Medical Center | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
| AU2020327043A1 (en) * | 2019-08-08 | 2022-02-24 | Cedars-Sinai Medical Center | Methods of improving organ function |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| AU2021381360A1 (en) * | 2020-11-20 | 2023-06-22 | Csl Behring Gmbh | Method for treating antibody-mediated rejection |
| CN113035369B (zh) * | 2021-03-10 | 2021-12-03 | 浙江大学 | 一种肾移植抗感染药物剂量预测模型的构建方法 |
| JP2024525084A (ja) | 2021-07-09 | 2024-07-09 | ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． | Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療 |
| WO2024152030A1 (en) * | 2023-01-13 | 2024-07-18 | The Uab Research Foundation | Crossmatching for porcine xenotransplantation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
| US20090118162A1 (en) | 2005-06-07 | 2009-05-07 | Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
| RS53864B1 (sr) * | 2006-03-02 | 2015-08-31 | Alexion Pharmaceuticals, Inc. | Produžavanje preživljavanja alografta inhibiranjem aktivnosti komplementa |
| DK2758076T3 (en) * | 2011-09-24 | 2019-04-01 | Csl Behring Gmbh | COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR |
| CA2901225C (en) * | 2013-03-08 | 2023-09-19 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| BR112015023207A8 (pt) * | 2013-03-15 | 2018-01-23 | Shire Viropharma Inc | composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase. |
| NZ719724A (en) * | 2013-11-22 | 2022-08-26 | Takeda Pharmaceuticals Co | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
-
2014
- 2014-11-21 NZ NZ719724A patent/NZ719724A/en unknown
- 2014-11-21 ES ES14809567T patent/ES2708655T3/es active Active
- 2014-11-21 NZ NZ759187A patent/NZ759187A/en unknown
- 2014-11-21 JP JP2016532586A patent/JP6431912B2/ja active Active
- 2014-11-21 AU AU2014352846A patent/AU2014352846B2/en active Active
- 2014-11-21 DK DK14809567.2T patent/DK3071219T3/en active
- 2014-11-21 HR HRP20190184TT patent/HRP20190184T1/hr unknown
- 2014-11-21 CA CA2930964A patent/CA2930964A1/en not_active Abandoned
- 2014-11-21 BR BR112016011499-0A patent/BR112016011499A2/pt not_active Application Discontinuation
- 2014-11-21 ME MEP-2019-31A patent/ME03318B/me unknown
- 2014-11-21 US US14/550,075 patent/US9895428B2/en active Active
- 2014-11-21 RS RS20190148A patent/RS58343B1/sr unknown
- 2014-11-21 EP EP22188379.6A patent/EP4162947A1/en not_active Withdrawn
- 2014-11-21 KR KR1020167013463A patent/KR102312817B1/ko active Active
- 2014-11-21 MX MX2016006656A patent/MX378834B/es unknown
- 2014-11-21 SI SI201431066T patent/SI3071219T1/sl unknown
- 2014-11-21 SM SM20190042T patent/SMT201900042T1/it unknown
- 2014-11-21 LT LTEP14809567.2T patent/LT3071219T/lt unknown
- 2014-11-21 HU HUE14809567A patent/HUE041809T2/hu unknown
- 2014-11-21 CN CN202010018792.0A patent/CN111388655A/zh active Pending
- 2014-11-21 KR KR1020217032180A patent/KR102384814B1/ko active Active
- 2014-11-21 WO PCT/US2014/066784 patent/WO2015077543A1/en not_active Ceased
- 2014-11-21 CN CN201480063697.5A patent/CN105744949A/zh active Pending
- 2014-11-21 EP EP18205998.0A patent/EP3494988B1/en active Active
- 2014-11-21 PL PL14809567T patent/PL3071219T3/pl unknown
- 2014-11-21 SG SG10201804326SA patent/SG10201804326SA/en unknown
- 2014-11-21 PT PT14809567T patent/PT3071219T/pt unknown
- 2014-11-21 EP EP14809567.2A patent/EP3071219B1/en not_active Revoked
-
2016
- 2016-05-20 MX MX2021000332A patent/MX2021000332A/es unknown
-
2017
- 2017-12-18 US US15/844,850 patent/US20180104319A1/en not_active Abandoned
-
2018
- 2018-10-15 JP JP2018194167A patent/JP6620206B2/ja active Active
- 2018-11-15 JP JP2018214342A patent/JP2019023233A/ja not_active Withdrawn
-
2019
- 2019-01-29 CY CY20191100119T patent/CY1121298T1/el unknown
-
2020
- 2020-01-02 AU AU2020200015A patent/AU2020200015B2/en active Active
- 2020-08-03 US US16/983,998 patent/US20200360495A1/en not_active Abandoned
-
2021
- 2021-01-29 JP JP2021012833A patent/JP2021063141A/ja not_active Withdrawn
-
2022
- 2022-10-11 JP JP2022163044A patent/JP2022179637A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537380A5 (https=) | ||
| JP7788114B2 (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| Winston et al. | Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients | |
| Johnson et al. | Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis | |
| Al Jarroudi et al. | Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases | |
| Mahmud et al. | Antibody immunosuppressive therapy in solid-organ transplant: Part I | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| KR20110074898A (ko) | 염증을 치료하는 방법 | |
| Liao et al. | Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review | |
| JP2017506626A5 (https=) | ||
| JP2021063141A (ja) | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 | |
| Zanwar et al. | Ixazomib: a novel drug for multiple myeloma | |
| Chakraborty et al. | Emerging therapeutic interventions for idiopathic pulmonary fibrosis | |
| Snell et al. | A randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation | |
| JP2014505056A5 (https=) | ||
| CN109640959A (zh) | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 | |
| Parrondo et al. | Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives | |
| Sadaka et al. | Proteasome inhibition for antibody-mediated allograft rejection | |
| Oury et al. | Protective effect of ticagrelor against infective endocarditis induced by virulent Staphylococcus aureus in mice | |
| Niemeyer et al. | Long-term safety, tolerability and efficacy of daclizumab (Zenapax®) in a two-dose regimen in liver transplant recipients | |
| Hsu et al. | Therapeutic effects of Anti-PD1 immunotherapy on hepatocellular carcinoma under administration of tacrolimus | |
| Terpos et al. | Multiple myeloma: clinical updates from the American Society of Hematology Annual Meeting 2016 | |
| Kaufman et al. | Induction of immune tolerance in living related human leukocyte antigen–matched kidney transplantation: A phase 3 randomized clinical trial | |
| Wamala et al. | Recombinant anti-monkey CD3 immunotoxin depletes peripheral lymph node T lymphocytes more effectively than rabbit anti-thymocyte globulin in naive baboons | |
| Chong et al. | From bench to bedside: reversing established antibody responses and desensitization |